Tirzepatide
For educational and research reference only. Not medical advice. Not for human or animal use. Research peptides are Research Use Only (RUO).
Amino Acid Sequence
39 amino acid dual agonist peptideAn interactive map of key discoveries, clinical trials, and major findings across 7 research milestones.
Tirzepatide was developed by Eli Lilly as the first dual GIP/GLP-1 receptor agonist, engineered with a C20 fatty diacid for once-weekly dosing.
Timeline compiled from published research literature for educational reference. Dates reflect first major publication or event; subsequent research continues to refine findings.
Tirzepatide is a groundbreaking peptide that works on two gut hormone systems simultaneously — GIP and GLP-1 — rather than just one. Imagine two separate walkie-talkie channels that your gut uses to communicate with your brain about fullness and blood sugar. Previous medications only used one channel. Tirzepatide is the first to use both at the same time, which appears to produce stronger effects than either channel alone.
Tirzepatide is a dual agonist that activates both the GIP receptor and the GLP-1 receptor. GIP receptor activation enhances insulin secretion and may contribute to fat metabolism and energy expenditure. The combined activation of both pathways is hypothesized to produce additive or synergistic metabolic effects beyond GLP-1 agonism alone.
Extensive Phase III clinical trial programs (SURPASS for diabetes, SURMOUNT for obesity). FDA-approved as Mounjaro® (diabetes, 2022) and Zepbound® (obesity, 2023). Clinical trials demonstrated unprecedented weight loss and glycemic improvements.
Preclinical pharmacology established the dual agonist mechanism and favorable metabolic profile.
Comprehensive receptor binding and signaling studies demonstrating balanced GIP and GLP-1 receptor agonism.
Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both the GIP receptor and the GLP-1 receptor. This dual mechanism is a fundamental pharmacological difference — tirzepatide is a "twincretin" while semaglutide is a single incretin mimetic.
Engineered for once-weekly dosing with a long half-life (~5 days). C20 fatty diacid moiety enables albumin binding for extended circulation.
Research Use Only
For educational and research reference only. Not medical advice. Not for human or animal use. Research peptides are Research Use Only (RUO).